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In the last few years, the number of bacteria with enhanced resistance to conventional
antibiotics has dramatically increased. Most of such bacteria belong to regular microbial
ﬂora, becoming a real challenge, especially for immune-depressed patients. Since the
treatment is sometimes extremely expensive, and in some circumstances completely
inefﬁcient for the most severe cases, researchers are still determined to discover novel
compounds. Among them, host-defense peptides (HDPs) have been found as the ﬁrst
natural barrier against microorganisms in nearly all living groups. This molecular class has
been gaining attention every day for multiple reasons. For decades, it was believed that
these defense peptides had been involved only with the permeation of the lipid bilayer
in pathogen membranes, their main target. Currently, it is known that these peptides can
bind to numerous targets, as well as lipids including proteins and carbohydrates, from the
surface to deep within the cell. Moreover, by using in vivo models, it was shown that
HDPs could act both in pathogens and cognate hosts, improving immunological functions
as well as acting through multiple pathways to control infections. This review focuses on
structural and functional properties of HDP peptides and the additional strategies used
to select them. Furthermore, strategies to avoid problems in large-scale manufacture by
using molecular and biochemical techniques will also be explored. In summary, this review
intends to construct a bridge between academic research and pharmaceutical industry,
providing novel insights into the utilization of HDPs against resistant bacterial strains that
cause infections in humans.
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INTRODUCTION
Infectious diseases caused by fungi and bacteria have affected
humanity since the early days of civilization. Nevertheless, the dis-
covery of penicillin by Fleming (1929) provided a potent defense
in mammalian survival against pathogens. Based on penicillin,
several other molecules and different antibiotic classes have been
developed. However, all these agents have lost efﬁciency and are
becoming useless against resistant bacterial strains.
Antimicrobial peptides (AMPs) have arisen as an alternative
strategy for the treatment of infections caused by super bugs
(Arias and Murray, 2009). AMPs are natural antibiotics found
in microorganisms, plants, and animals (Hancock and Chapple,
1999). They can be structurally classiﬁed, being formed by α-
helices, β-sheets, extended structures, or disordered loops. More-
over, these peptides could also be classiﬁed by physical–chemical
properties: cationic, anionic, and amphipathic (Peters et al., 2010).
Mostly, cationic AMPs show their antimicrobial activity as a result
of lipid bilayer disruption. Nevertheless they may also act on var-
ious cell targets, in some cases being considered promiscuous
molecules (Huang et al., 2010). In the last few years the con-
ventional idea that peptides possess an unconditional structure
directly related to a particular function clashes with the peptide’s
ability to change and develop new functions. Considering these
contrasting ideas, the knowledge of peptide promiscuity, in which
multiple functions may be associated with a sole structure, has
been gaining consideration in several research ﬁelds including
the development of antibiotics. Indeed, several AMPs have shown
their wide range of functions that are able to control numerous
target pathogens simultaneously and in different conditions (as
reviewed by Franco, 2011). Moreover, some peptides, in addition
to activity against pathogens, also have shown multiple activi-
ties related to host innate immunity, called host-defense peptides
(HDPs; Hancock et al., 2006).
Host-defense peptides are relatively small compounds, with
12–50 amino acid residues, positive net charge (+2 to +9),
and are isolated from single-celled microorganisms, invertebrates,
plants, amphibians, birds, ﬁshes, and mammals including humans
(Hancock and Sahl, 2006). Furthermore, HDPs are classiﬁed
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into various groups according to a three-dimensional structure
arrangement that includes α-helices (magainin, cecropin, and
cathelicidin), β-sheets (hepcidin, human α-defensin 1), a mix-
ture of α-helices/β-sheets (humanβ-defensins 1), cyclic (cyclotides
and catestatin), as well as extended and ﬂexible loops (e.g., indoli-
cidin; Figure 1; Hancock et al., 2006). In addition to their direct
action against microorganisms, as previously described, HDPs
also present activities related to innate immunity. These include
the induction or modulation of pro-inﬂammatory cytokine
and chemokine production, chemotaxis, apoptosis, inﬂamma-
tory response inhibition, recruitment, and stimulation of prolif-
eration of macrophages, neutrophils, eosinophils, T lymphocyte
activation, and differentiation of dendritic cells (DCs; Bowdish
et al., 2005; Nijnik et al., 2009). One property that makes HDPs
extremely attractive molecules for therapeutic use is that they are,
in general, non-toxic to mammalian cells. The basis for this selec-
tivity appears to be related to the lipid composition of the target
membrane (ﬂuidity, negative charge, and the absence/presence of
cholesterol; Nicolas, 2009). The negative charge of a bacterial outer
membrane is an example of a typical HDP target. In contrast,
zwitterionic membranes, commonly found in plants and animals
are not normally accessible to HDPs (Matsuzaki, 1999; Zasloff,
2002). Furthermore, the presence of cholesterol in the mem-
brane may usually reduces HDP activity, since cholesterol helps
in lipid bilayer stabilization, thus reducing membrane ﬂuidity and
ﬂexibility (Matsuzaki, 1999).
This concept, in addition to peptide promiscuity, adds remark-
able value to peptide antibiotic compounds, which have been
shown to be much more useful for an organism’s protection
than merely membrane disruptors. The phenomenon of protein
promiscuity, in which several functions are associated with a single
peptide structure, has gained attention in several research ﬁelds,
especially in the area of drug design (Franco, 2011). From this
perspective, this review focuses on these compounds from var-
ious sources in order to shed some light on the structure and
the observedmechanismof action. Furthermore, biotechnological
and pharmaceutical potential will also be evaluated and discussed,
as well as isolation and production in large-scale.
PLANT HOST-DEFENSE PEPTIDES
Plants have an arsenal of peptides in their own primitive innate
immune system that is completely different from that of ani-
mal systems. Since plants are unable to synthesize antibodies,
these peptides form an efﬁcient barrier against bacteria, fungi,
and insects. Furthermore, along with these peptides, plants have a
set of physical and chemical barriers that act together to prevent
infection (Sels et al., 2008). The plant cell wall is the ﬁrst level of
defense, formed by a complex network of proteins and polysac-
charides. Even during a pathogen attack, plants are able to deposit
callose, otherwise known as the polysaccharide β-1,3-glucan, at
the infection site and further synthesize lignin-like polymers, thus
reinforcing the wall (Hématy et al., 2009). Callose is a polysaccha-
ride that acts in response to multiple biotic and abiotic stresses,
as well as during a variety of processes in plant development
(Chen and Kim, 2009). When a pathogen crosses through the
cell wall, plants can induce a hypersensitive response (HR) or
synthesize antibacterial and antifungal compounds for infection
control. HR is characterized by an induced cell death at the point
of pathogen contact and can be related to resistance (Mur et al.,
2008). The antimicrobials produced are: ROS, secondary metabo-
lites, proteins, and peptides were found (Benko-Iseppon et al.,
2010).
In addition to providing a primary defense function, sev-
eral plant peptides have shown a side biological property that
could be exploited for biotechnological applications. This abil-
ity, in which a single structure provides multiple functions, has
been denominated peptide promiscuity (Franco, 2011). Several
plant peptides that show medicinal properties include defensins,
thionins, and cyclotides. These peptides have shown a wide diver-
sity of simultaneous activities, in addition to antibacterial and
antifungal properties, which includes anti-HIV (Wong and Ng,
2006), antitumor (Lin et al., 2010), leishmanicidal (Berrocal-Lobo
et al., 2009), uterotonic (Gran, 1973), anthelmintic (Colgrave et al.,
2009), and neurotensin blocking activities (Witherup et al., 1994).
However, no plant peptide was found to have both simultane-
ous antimicrobial and immunomodulatory activities inmammals,
clearly limiting the classiﬁcation of HDPs into the plant king-
dom.Nevertheless,webelieve that this lackof immunomodulatory
activity is related to the low quantity of studies in this ﬁeld and
not to the intrinsic properties of these promiscuous peptides in
plants.
Plant AMPs show common properties that are characterized
by a low molecular mass (around 10 kDa), cationic charge, and
the presence of cysteine residues that are linked through disulﬁde
bonds, thus stabilizing the molecular structure (Padovan et al.,
2010). However, defensins, cyclotides, and thionins have speciﬁc
and typical structures that will be described below.
Defensins are ubiquitous peptides in plant species, showing
several nuanced functions (Padovan et al., 2010). Defensins are
cationic peptides with pI values around 9.0 and are 45–55 amino
acids residues long, with molecular masses ranging between 5 and
7 kDa (Carvalho Ade and Gomes, 2009). The common tertiary
structure consists of a triple-stranded antiparallel β-sheet, and one
α-helix which in most cases is stabilized by either three, four, or
ﬁve disulﬁde bonds (Figure 2A; Garcia-Olmedo et al., 1998). The
primary sequence is low conserved between different defensins,
and this may explain the diverse biological activities reported
(Padovan et al., 2010). Some of the defensins can be classiﬁed as
promiscuous peptides (Franco, 2011) having multiple-biological
functions (Table 1). In addition to defensins, thionins are peptides
with low molecular masses (5 kDa), 45–47 amino acid residues in
length and can present three or four conserved disulﬁde bonds
that stabilize the structural fold (Padovan et al., 2010). Due to their
sequences and disulﬁde bonds patterns, thionins are classiﬁed into
ﬁve structural types (I–V). The conserved structure is formed by
two antiparallel α-helices, one β-turn, and one antiparallel β-sheet
(Figure 2B; Padovan et al., 2010). Some thionins demonstrated
unusual biological functions (Table 1).
Finally, cyclotides are small peptides characterized by 28–37
amino acids long, presenting three disulﬁde bonds, and a cyclic
backbone formed through the linking of amino and carboxyl-
terminus (Craik, 2010). This structure confers to the cyclotides a
strong and stable molecular structure (Figure 2C). Although M.
cochinensis trypsin inhibitors have been classiﬁed as cyclotides due
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FIGURE 1 | An overview of the major structural classes of host-defense peptides including (A) α-helices, (B) β-sheets, (C) a mixture of
α-helices/β-sheets structures, (D) cyclic, and (E) extended structures. Disulﬁde bonds are represented in ball and stick.
FIGURE 2 |Three-dimensional structures of plant antimicrobial
peptides. (A) Defensin – Vigna radiata defensin-2, (B)Thionin – Viscum
album viscotoxin A3, and (C) Cyclotide – Viola odorata violacin A. Disulﬁde
bonds are represented in ball and stick.
to their structural similarities, theydonotdisplay sequencehomol-
ogy to the previously identiﬁed plant cyclotides (Felizmenio-
Quimio et al., 2001).Until now, cyclotideswere found inViolaceae,
Rubiaceae, Apocynaceae, Cucurbitaceae, Poaceae, and Fabaceae
families (Craik, 2010). Despite their conserved molecular struc-
tures, these cyclic peptides have shown diverse biological functions
in addition to insecticidal activity (Table 1).
HOST-DEFENSE PEPTIDES AND THEIR MULTIPLE ROLES IN
ANIMAL IMMUNE DEFENSE
Previously, it was believed that the direct antimicrobial activity of
AMPs was essential for their role in innate immunity and host-
defense. However, some studies have shown that peptide concen-
trations found in various body parts, such as mucous for example,
are relatively low when compared with those used in in vitro stud-
ies (Hirsch et al., 2008). It has been known that, in addition to this
activity against pathogens,HDPsmay also have an indirect antimi-
crobial effect, as previously cited (Auvynet and Rosenstein, 2009).
The human cathelicidin LL-37 (hCAP18), a well-characterized
multifunctionalHDP, is constitutively produced by leukocytes and
induced in barrier organs upon inﬂammation and infection, thus
being essential for immune response to injury and tissue infec-
tion (Bowdish et al., 2005). Another well-characterized HDP is the
human β-defensin-2 (hBD2). It is known that this peptide plays an
important role in immune response at different mucosal surfaces
and also in the skin barrier (Ganz, 2003). Among the LL-37 and
hBD2 wide activities spectrum, the induction of histamine and
prostaglandin D2 released by mast cells after stimulating HDPs
have important roles in microbial invasion response (Niyonsaba
et al., 2001). Concomitantly to these activities, LL-37 induces ker-
atinocytes to release IL-1β, IL-8, TNF-α, IL-6, colony-stimulating
factor and granulocyte–macrophage (GM-CSF), and immature
DCs to release TNF-α and IL-6 (Braff et al., 2005). However,
the peptide response is dependent on the cell type that is stud-
ied. For example, in human peripheral blood mononuclear cells
(PBMCs),LL-37 inhibits the expressionof pro-inﬂammatorymol-
ecules, such as TNF-α and IL-6, and nuclear translocation of
NFκB p50/p65 induced by toll-like receptor (TLR)-2 and TLR-4 in
response to lipoic acid (LA) and lipopolysaccharide (LPS), respec-
tively. This inhibition is an important event in severe microbial
infections, such as sepsis (Mookherjee et al., 2006). In addition,
the hBD2 also acts on TLRs, functioning as an endogenous TLR-4
ligand, further activating immature DCs, and triggering a strong
Th1 response (Biragyn et al., 2002).
Moreover, other not-so-well-studied peptides also act signif-
icantly on the mammal immune system. Human α-defensins
(HNP-1, HNP-2, and HNP-3) and β-defensins (hBD3 and hBD4)
are involved in neutrophil and monocyte recruitment, while mast
cells may be attracted to the infection site by LL-37, HNP-1–3,
and hBD2 (Chen et al., 2007). Besides, human α-defensins and β-
defensins are chemotactic for immature DCs and memory T cells
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Table 1 | Plant HDPs and their multiple activities related to host-protection.
Peptide name Source Activity Possible application Reference
DEFENSINS
– Phaseolus angularis Inhibit tumor cell lines L121 and MBL2 Antitumor therapy Ma et al. (2009)
Limenin P. limensis Inhibit myeloma (M1) and leukemia (L1210) cell
lines and inhibit HIV-1 reverse transcriptase
Antitumor and antiviral
therapy
Wong and Ng (2006)
Lunatusin P. lunatus Inhibit breast cancer cell line (MCF-7), the activity
of HIV-1 reverse transcriptase, and the translation
in a cell-free rabbit reticulocyte lysate system
Antitumor and antiviral
therapy
Wong and Ng (2005)
– P. vulgaris Inhibit hepatom (HepG2), breast (MCF-7), colon
(HT29), and cervical cancer (SiHa) cells, and
inhibit HIV-1 reverse transcriptase activity
Antitumor and antiviral
therapy
Lin et al. (2010)
THIONINS
Without name Triticum aestivum Inhibit the proliferation of Leishmania donovani Leishmanicidal
therapy
Berrocal-Lobo et al. (2009)
PTH1 Solanum tuberosum Inhibit the proliferation of L. donovani Leishmanicidal
therapy
CYCLOTIDES
Kalata B1 Oldenlandia afﬁnis Uterotonic, anti-HIV activities, and anthelmintic
activity against parasites of sheep, humans, and
dogs
Anthelmintic, antiviral,
and uterotonic therapy
Gran (1973), Colgrave et al. (2008),
Colgrave et al. (2009)
Kalata B6 O. afﬁnis Anthelmintic activity against gastrointestinal par-
asites of sheep, humans, and dogs
Anthelmintic therapy Colgrave et al. (2008), Colgrave
et al. (2009)
CirA Chassalia parvifolia Anti-HIV activity Antiviral therapy Gustafson et al. (1994)
CirB C. parvifolia Anti-HIV activity Antiviral therapy
Cyclopsychotride Psychotria longipes Ability to block neuropeptide neurotensin Antipsychotic therapy Witherup et al. (1994)
Cycloviolacin O2 Viola biﬂora In vitro antitumor activity Antitumor therapy Gerlach et al. (2010)
(Yang et al., 2002), where human α-defensins selectively induce
the migration of human cells CD4+, CD45+, and CD8+ naive,
suggesting that HDPs play an important role in mobilizing and
amplifying the innate and adaptive immunity against microbial
invasions (Yang et al., 2001). Indolicidin, for example, inhibits
TNF-α secretion by macrophages in response to LPS treatment
(Bowdish et al., 2005). Similar to the effects of LL-37, indolicidin
induces the production of IL-8 in human bronchial epithelial
cells 16HBE14o−. They also have demonstrated that the pep-
tide bactenecin 2A, a member of bactenecins family, presented
chemotactic activity over TH1 cells. Dermcidin-1L, another HDP
example, stimulates keratinocytes to secrete TNF-α, IL-8,CXCL10,
and CCL20 (Niyonsaba et al., 2009). Another group of peptides
with strong antimicrobial activity and immunomodulatory activ-
ity are protegrins. Protegrins-1 and -3 promote rapid and efﬁcient
mature IL-1 beta release. Both peptides also promote modiﬁcation
in the morphology of monocytes and a loss of latency of the cell
membranes (Perregaux et al., 2002).
Recent data have shown that HDPs are multifunctional mole-
cules at different tissue levels, acting in the neuroendocrine system.
Cathelicidins and defensin mRNA were widely found in the brain
(Su et al., 2010), suggesting that HDPs could be involved in innate
immune brain defense. Recently, it has been discovered that some
neuropeptides play an important role in antimicrobial activity.
Enkelytin, a pro-enkephalin-derived peptide, has shown strong
activity against Gram-positive bacteria and also has acted as a link
of communication and interaction between nervous, endocrine,
and immune systems (Goumon et al., 1996). Met5-enkephalin
peptide stimulated the proliferation of natural killer cells, B- and
T-lymphocytes, migration of monocytes, lymphocytes, and neu-
trophils, and also stimulated the secretion of IL-6 by monocytes
(Kamphuis et al., 1998). Recently, Shan et al. (2011) suggested
that Met5-enkephalin appeared to be involved in the regulation
between the neuroendocrine and immune systems, modulating
several cell functions related to innate and adaptive immunity.
They also have found that Met5-enkephalin activated CD4+T
cells by increasing the expression of delta receptors. Moreover,
this peptide also induced DC maturation through the expression
of surface molecules (MHC class II, CD86, CD40), stimulated
the production of IL-12, and down-regulated the intracellular
acid phosphatases (ACP) in DCs. In addition, Met5-enkephalin
(alone or in combination with either IL-2 or IFN-γ) up-regulated
the proliferation of CD4+T cells and increased production of
interferon-γ in these cells. The peptide leucine-enkephalin stim-
ulated the production of T helper cells and cytotoxic T cells
(Sizemore et al., 1991).
Among peptides with antimicrobial activity described in the
neuroendocrine system, those derived from chromogranins have
been highlighted. They are members of the granin family, which
are acidic proteins present in secretory vesicles in the endocrine
and immune systems (Shooshtarizadeh et al., 2010). Chromo-
granins have shown multiple-biological activities including neu-
roendocrine activity, modulation of homeostatic processes such
as regulation of calcium metabolism and glucose, gastrointestinal
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motility, nociception, strong activity in tissue repair, and inﬂam-
matory response mediation. More recently, peptides derived from
chromogranins could act as defense agents during infections of
bacteria and fungi. Moreover, chromogranin-derived peptides
have shown activity in innate immunity, being able to activate
polymorphonuclear neutrophils, mediate the monocyte chemo-
taxis, and induce microglial cell activation (Shooshtarizadeh et al.,
2010). Peptides derived from chromogranins have shown special
activity against pathogens commonly found in the skin, reveal-
ing that the expression of these peptides may be performed by
keratinocytes. In these cells, chromogranin A fragments gener-
ated catestatin: a broad-spectrum antimicrobial peptide. These
fragments induce monocyte chemotaxis and act on the produc-
tion of cytokines and chemokines by mast cells (granulocyte–
macrophage colony-stimulating factor, monocyte chemotactic
protein-1, macrophage inﬂammatory protein-1α, macrophage
inﬂammatory protein-1β, and chemokine – C-C motif – ligand
2, 3, and CCL2, CCL3, CCL4). Furthermore, it also stimulated
keratinocyte interleukin-8 production through the activation of
mitogen-activated protein kinases (Radek et al., 2008; Shooshta-
rizadeh et al., 2010). Other peptides derived from chromogranins,
termed vasostatins, have shown deleterious activity against Gram-
positive bacteria, ﬁlamentous fungi, and yeasts (Dondossola et al.,
2010). These studies have demonstrated that a neuroendocrine
peptide may have antimicrobial activity against a wide variety
of skin pathogens and may be up-regulated in the lesion. These
data have demonstrated a direct link between the neuroendocrine
and immune system (Shooshtarizadeh et al., 2010). Finally, the
expression of catestatin in mice skin resulted in higher protec-
tion against infection and injury. Catestatin is a 21-amino acid
residue,which ismade endogenously from the proteolytic cleavage
of chromogranin A (Radek et al., 2008).
Studies have shown that members of the neuropeptide
bombesin family, in addition to direct activity againstmicroorgan-
isms, mediate a variety of biological activities in the gastrointesti-
nal tract and central nervous system (CNS) of mammals, including
smooth muscle contraction, hormone secretion, cell proliferation
stimulation, and central-homeostatic mechanism regulation (Su
et al., 2010). Another HDP family found in mammalian brains
are hepcidins, which besides having direct antimicrobial activity,
also reduce secretion of TNF-α, IL-1α, IL-1β, and IL-6 by regulat-
ing the COX-2 gene and PDE4D by using mechanisms dependent
on pERK1/2 in macrophage cells (Su et al., 2010). In this view,
due to LPS stimulation, a signiﬁcant increase in hepcidin mRNA
expressionwas observed in cortex and substantia nigra. These ﬁnd-
ings suggest that the CNS can use many peptides as anti-infective
and immunomodulatory agents by delivering them quickly and
accurately to innervated sites, indicating a new dimension for an
immunomodulatory role for neuropeptides in inﬂammatory and
immune responses (El Karim et al., 2008).
HOST-DEFENSE PEPTIDES: FUNDAMENTAL MOLECULES IN
RESPONSE TO HUMAN MICROBIAL INFECTIONS
HDPs are evolutionarily ancient molecules that reinforce the
human innate immune system against microbial invasion (Nijnik
et al., 2009). A constitutive HDP expression has been observed in
phagocytic cells and in body tissues (Figure 3). This occurrence
FIGURE 3 | Distribution of host-defense peptides described in human
body.The host-defense peptides have a wide distribution in human body,
being found mainly in skin, mucous membranes, blood, nervous system,
and liver.
happens particularly at human interfaces between the environ-
ment and the host, such as skin and mucosal membranes (Hirsch
et al., 2008). HDP synthesis and release are regulated by micro-
bial stimuli, cytokines, neuroendocrine signals, and epigenetic
regulation (Ganz, 2003).
Along these lines, intestinal mucosal pathologies, such as
Crohn’s disease and intestinal inﬂammation, result from the
reduction of α-defensin expression in the small intestine (Inaba
et al., 2010). The protective role of α-defensins against patho-
genic bacteria in intestinal infections has been certiﬁed in α-
defensin-deﬁcient mice, since mice became more susceptible to
Salmonella typhimurium infections (Inaba et al., 2010). More-
over, hBD1 and hBD2 are important HDPs in gastric-intestinal
mucosa. The expression of both peptides increased in the gastric
antrum mucosa, which is commonly induced by gastritis caused
via Helicobacter pylori (Bajaj-Elliott et al., 2002).
Regarding HDPs produced in human skin, patients with infec-
tious cellulitis presented an increased expression of LL-37 and
β-defensin in comparison with those normal skins (Stryjewski
et al., 2007). This datum suggests that HDPs may provide addi-
tional protection against microbial dissemination, conﬁning the
focus of infectious cellulitis to a single location. However, patients
with atopic dermatitis presented an absence or reduced expres-
sion of LL-37, hBD2, hBD3, and dermicidin (Bernard and Gallo,
2011). These ﬁndings suggest that patient susceptibility to atopic
dermatitis in skin infections could be higher due to a signiﬁcant
increase in either bacterial colonization, fungal, or viral infections
(Bernard and Gallo, 2011). Recent studies have detected high lev-
els of human β-defensin, hBD2, hBD3, and psoriasin in cutaneous
infections after skin surgery (Kesting et al., 2010). Expression of
hBD2-3 is reduced in burn wounds, while the expression hBD1 is
unchanged (Milner and Ortega, 1999). However, the skin’s lower
layers continue to express hBD1-3 after wound recovery, main-
taining a barrier against infection and preventing burn sepsis
(Poindexter et al., 2006).
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Sepsis is a major cause of mortality and high hospital costs
and, despite the efforts that have been made by public health
authorities in recent decades, the incidence of this syndrome con-
tinues to increase year after year due in particular to the increasing
emergence of microorganisms resistant to the available antibiotics
(Barnato et al., 2008). Several HDPs have been reported to mod-
ulate the host response to bacterial sepsis. LL-37 acted as a potent
inﬂammation molecule mediator, protecting mice and rats from
the lethal effects of endotoxemia and intra-abdominal sepsis. This
protection occurs due to a reduction in the levels of TNF-α and
LPS in plasma, which inhibit the activation of macrophages by
LPS, lipoteichoic acid (LTA), and non-mannose-capped lipoara-
binomannan, as well as regulating the expression of coding genes
and receptors (CXCR-4, CCR2, and IL-8RB) of chemokines in
macrophages (Torossian et al., 2007). The main mechanism of
TNF-α expression inhibition by LL-37 in mice is believed to occur
by the blocking of LBP-mediated transport of LPS in CD14+
cells (Nagaoka et al., 2001). HDPs buforin II, indolicidin, and
cecropin B have shown effectiveness in the treatment of rats with
septic/endotoxic shock caused by multi-resistant Escherichia coli
and LPS, signiﬁcantly reducing the plasma levels of endotoxin and
TNF-αwhen compared to animals treated with piperacillin (Valle-
spi et al., 2003). Limulus anti-LPS factor (LALF), a peptide isolated
from the horseshoe crab, could increase the survival of mice after
administration of a lethal P. aeruginosa dose. This activity may be
correlated with a decreased TNF-αmRNA synthesis and elevation
of systemic IL-2, IL-12, and IL-13 into animal spleen and livers
(Vallespi et al., 2003). Mice with endotoxic shock derived from
an LPS and treated with S-thanatin, an insect peptide, showed
reduced levels of TNF-α accompanied by a signiﬁcant increase
(80%) of animal survival (Wu et al., 2011a). In another study, ani-
mals infectedwithmulti-resistantP. aeruginosa and further treated
with a single dose of tachyplesin III isolated from horseshoe crabs
has shown reduced TNF-α levels in contrast to a clear survival
increase (Cirioni et al., 2007). Treatment of amphibian source
magainins (I, II, and III) in septic/endotoxic shock signiﬁcantly
reduced the concentrations of endotoxin and TNF-α in plasma
rats, thus increasing host survival (Cirioni et al., 2002). These data
suggest that peptides that could act against septic shock could be
found at different sources and their activities are clearly related
to TNF-α inhibition and endotoxin neutralization, which seem to
be important mechanisms that increase the survival of infected
animals.
NOVEL AND CLASSICAL STRATEGIES FOR HDPs ISOLATION
Currently, several limitations have driven the area in the devel-
opment and production of HDP molecules away from natural
peptides to the shorter and more stable synthetic forms. Libraries,
synthetic strategies, and peptidomimetic technologies are being
reﬁned in order to overcome current limitations (Yeung et al.,
2011).
Traditionally, since the beginning in 1928, with the discovery
of lantibiotic Nisin produced by a Lactococcus lactis, until nearly
the end of the twentieth century, the discovery and identiﬁca-
tion of peptide antimicrobial molecules from natural sources with
pharmaceutical anti-infectious purposes have been carried out
by conventional biochemical procedures. Both goals frequently
started from an expected and conﬁrmed biological activity: gener-
ally a direct inhibition of microbial growth of bacteria, virus, fungi,
and parasites (using a medical concept of microbes). This primary
evaluation of crude extracts was the starting point for combined
steps of clariﬁcation, salt or acidprecipitation,ultraﬁltration,chro-
matographic puriﬁcation, and the eventual available structural
characterization. This approach, on the other hand, required an
important volume of specimen, whole bodies or parts, to assure
a signiﬁcant level of antimicrobial activity. These procedures were
achieved representing a real ecological challenge for the differ-
ent life kingdoms if, ﬁnally, a large-scale pharmaceutical industry
could be implemented for sustaining permanent production based
on such an animal source (Bulet, 2008). Such natural sources were,
in principle, associated with invertebrates, since HDPs are their
major humoral tool to defeat a vast microbial challenge and must
be effective in the absence of acquired immunity (Otero-Gonzalez
et al., 2010). Today, multiple AMPs have been explored also for
their immunomodulatory properties even when they are, in vivo,
less potent for directly killing microbes than their conventional
antibiotic counterparts (Lai and Gallo, 2009).
New trends in research are currently categorizing the discovery
of new HDPs through the use of biological peptide libraries, thus
providing a larger andmore diverse quantity of molecules for eval-
uation. Such libraries based on phage (Pini et al., 2005), bacterial
(Betscheider and Zangen, 2005), or ribosome display (Xie et al.,
2006) are nevertheless time-consuming procedures and difﬁcult to
handle. In fact, a novelmethod for the identiﬁcationofAMPsusing
a phage library and bacterial magnetic particles has been reported
(Betscheider andZangen,2005; Pini et al., 2005).Using this library,
six antibacterial peptides speciﬁcally active against B. subtilis have
been identiﬁed. It was the ﬁrst attempt that showed the function-
ality of a magnetic selection of HDPs targeting the bacterial inner
membrane. Furthermore, these methodologies produce fusion
instead of individual peptides and, additionally, only amino acids
encoded in the genome can be used with a reasonable support of
biological diversity. A clear advantage of these approaches is that
peptides are biologically synthesized, avoiding the use of expensive
chemicals and facilities (Mcphee et al., 2005). Furthermore, the
advances in the genomic area including next generation sequenc-
ing and improvements in databank and bioinformatics tools have
permitted the identiﬁcation of many different compounds includ-
ing HDPs. In a well-designed genetic approach reported in ﬂatﬁsh,
the identiﬁcation of active, novel antimicrobialmolecules has been
determined by screening both the genomic information and the
mRNA transcripts from a number of different sequences encod-
ingAMPs. Predictions of active peptide sequences from the genetic
information were the starting point for the production of chem-
ically synthesized peptides that have been tested for their cognate
activities.A very active peptidewas found to show inhibitory activ-
ity against a test panel of pathogens including antibiotic-resistant
bacteria and fungi (Patrzykat et al., 2003).
As an attempt to expand the efﬁciency of discovering novel
and effective HDPs, including unnatural HDPs, chemical peptide
libraries are open to amino acids not encoded in the genome, d-
amino acids, and even non-canonical amino acids. Screening large
numbers of peptides using a synthesis of peptide arrays on cellu-
lose membranes (SPOT technology) provides an extraordinary
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tool for characterizing large quantities of peptides for a partic-
ular biological activity (Hilpert, 2010). This improved method
using hydroxymethyl phenoxyacetic acid (HMPA) for 19 amino
acids and 4-(4-hydroxymethyl-3-methoxyphenoxy)-butyric acid
(HMPB) for proline, since acidic labile linkers in SPOT synthe-
sis have been developed. Using this approach, reduced side-chain
reactions, normally occurring during conventional alkaline pep-
tide cleavage of cellulose membranes, was achieved. This method
is suitable for synthesizing many thousands of different peptides
subsequently used for direct multiple-biological assays (Ay et al.,
2008).
Since the search for novel classes includes the puriﬁcation
process, the properties of target peptides such as hydrophobicity,
cationicity, and small size have been broadly used in their puriﬁ-
cation. As follows, reversed-phase chromatography, ion exchange,
and gel ﬁltration are commonly included in the puriﬁcation pro-
cedures for these molecules (Schroder, 2010). Although direct
interaction of HDPs with different target molecules such as LPS
(Gustafsson et al., 2010), lipid II (Schneider et al., 2010), and sphin-
golipid receptors are widely known (de Medeiros et al., 2010),
afﬁnity chromatography has not been widely used for their iso-
lation. The use of this type of chromatography may improve the
isolation of AMPs with desired afﬁnities for biomolecules. For
example, HDPs with the ability to bind LPS are very important
in the treatment of sepsis, as previously described (Giuliani et al.,
2010). However, the majority of molecules capable of inhibiting
LPS have been synthesized on the basis of the Limulus anti-
lipopolysaccharide factor (Andra et al., 2004). There is little doubt
that the rational use of the LPS-afﬁnity chromatography could
enhance thenumberof naturalHDPswith anti-LPS activity. In this
case, afﬁnity chromatography also acts as a screening procedure.
In fact, it has isolated lipopolysaccharide-binding proteins from
porcine milk and from the invertebrate hemolymph Tachypleus
tridentatus using a similar chromatographic principle (Shahriar
et al., 2006). Furthermore, HDPs are able to be induced, being
another HDP property that could be exploited in their puriﬁca-
tion (Lavine et al., 2005). In fact, the microbial challenge test of
different vertebrates and invertebrates permitted the isolation of
augmented HDPs (Isobe et al., 2009). Thus, it could be possible
to induce HDPs with a potent anti-proliferative activity against a
particular group of pathogens (Lemaitre et al., 1997). The induc-
tion of these molecules may reveal basal HDPs and facilitate their
puriﬁcation by augmenting the concentration levels for further
puriﬁcation. Traditionally, once a peptide sequence had been iden-
tiﬁed and/or partially puriﬁed from a natural source, a structural
approach had been applied with the aim to improve its antimi-
crobial activity and/or decrease its toxic or antigenic implications
for experimental tests in animals or initial human trials. In this
sense, amino acid substitutions based on the sequence data or on
the three-dimensional structure such as the replacing of arginine
residues with α-amino-3-guanidino-propionic acid of the natural
peptides may help to reduce serum AMPs degradation. The modi-
ﬁedpeptide stabilitywas increased bynearly 80%without affecting
the antimicrobial activity (Knappe et al., 2010). In a completely
different but valid approach (based on the membrane-binding
activity of most AMPs), cell membrane afﬁnity chromatography
has been reported to screen antibacterial peptide molecules from
plant extracts. In this case, cell membrane afﬁnity chromatogra-
phy was useful for primary screening of cell membrane receptors
according to its chromatographic retention. This constitutes one
of the ﬁrst reports on a high-throughput screening (HTS) of AMPs
by such a principle (Xiao et al., 2011).
High-throughput screening is a well-established method in the
bio-industry and is now used for basic and applied scientiﬁc
research (Figure 4). It involves the screening of large biologi-
cal and chemical libraries for activity against biological targets
by automation, miniaturized assays, and large-scale data process-
ing (Mayr and Bojanic, 2009). While HTS was initially applied to
relatively non-complex simple assays concerning single molecular
objectives or using afﬁnity interactions relationships,HTS has also
been applied to more integrated complex biological multicompo-
nent systems, such as whole-cell-based tests. The intense need for
novel and efﬁcient antimicrobial molecules highlights the exis-
tence of multi-drug-resistant microorganisms, where multiple-
target or cell-based assays are frequently desired, and thus is
obliging researchers to reﬂect on multi-target, high-throughput
technologies (Blondelle and Lohner, 2010). Clearly, an improved
understanding of non-lytic modes of HDP interaction with target
microbes will lead to the design and discovery of more effective
antimicrobial molecules (Marcos and Gandía, 2009). In the phar-
maceutical industry,HTSmeans challengingmillions of molecules
in massive automated applications. On the other hand, in a cur-
rent academic laboratory, it may imply screening only a small
quantity of peptides, mainly by conventional artisanal techniques.
HDP activity may be best described by the concept of “interfa-
cial activity” (Wimley, 2010). Structure–function relationships are
infrequently utilized. The next challenge is not the generation of an
extensive repertoire of molecules, but HTS employed to efﬁciently
identify the active members from a massive source. In general,
HTS could be divided into two categories: biological and non-
biological procedures (Rathinakumar and Wimley, 2010), which
will be discussed next.
IN VITRO AND IN SILICO BIOLOGICAL ASSAYS FOR THE
FUNCTIONAL EVALUATION OF HDPs
Broth dilution and agar diffusion methods, in which the activ-
ity of HDPs are directly estimated for the inhibition of microbial
growth in a nutritive broth, could be in principle amended for
HTS (Wiegand et al., 2008). Automated and massive variations
of such procedures have been established in order to scale the
number and diversity of HDPs to be veriﬁed. The use of lumi-
nescent bacteria for fast screening and characterization of short
cationic AMPs synthetically immobilized in cellulose using pep-
tide array technology has been developed (Hilpert et al., 2005).
In this unusual approach, the authors used bacteria expressing
the luciferase gene cassette (luxCDABE). Any synthetic peptide
decreasing the energy level within the microbial cell will cause a
quantiﬁable decrease in luminescence. The effectiveness of a tested
molecule, at different concentrations, is reﬂected by the decreas-
ing rate in luminescence. The assay is rapid and high-throughput
and has shown signiﬁcant correlation when compared with con-
ventional suspension inhibitory culture assays performed with the
samepeptides synthesized by standard solid-phase peptide synthe-
sis. Using this approach, 277 variants of the antimicrobial peptide
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FIGURE 4 | A typical “end point” high-throughput screening flow for searching novel host-defense peptides.
Bac2A (a 12-mer linear variant of the HDP bactenecin) were stud-
ied. The antimicrobial activity of Bac2A derivatives ranged from
superior to inactive compared to Bac2A (Hilpert et al., 2006). This
technology allowed for a decreased amount of time required to
convert leaded antimicrobial molecules into drugs.
In another interesting approach, a novel assay that had
exploited ﬂuorescence resonance energy transfer (FRET) was set
up for antimicrobial peptide screening. It took advantage of
changes in pH that occur in FRET efﬁciency due to the insta-
bility of increased yellow ﬂuorescent protein against the stability
of increased cyan ﬂuorescent protein in a reduced-pH environ-
ment. Evaluation of antimicrobial activity was achieved through
a difference of FRET efﬁciency between fusion molecules released
from disrupted bacteria. It represented a clear example applica-
ble to HTS of candidate peptide libraries (Kim and Cha, 2006).
In this line of thought, a high-throughput method for screening
cDNA libraries has been developed to detect possible AMPs. It
was based on a fast dye inclusion assay for determining a bacterial
viability loss. Colonies were grown on a membrane on a suitable
medium until full colony development. The membrane contain-
ing the array of colonies is transferred onto an inductive medium
containing a vital dye. Upon expression of any active peptides, the
cell membrane becomes susceptible and permits dye infusion to
induce visual identiﬁcation of positive peptides (Loit et al., 2008).
In this way, a random oligonucleotide library containing a poten-
tial pool of 100,000 peptides was screened. The authors found
three novel antibacterial peptides. One of them has shown mem-
brane disruption and bacterial aggregation activity (Loit et al.,
2010). Unfortunately, these HTSs are not available yet for other
HDP activities like immunomodulation or wounding repair. The
development of techniques in these areas will boost the insertion
of HDPs into the drug industry.
An early attempt for automating the screening of membrane-
relatedAMPswas reported inwhich a colorimetric sensor bywhich
particles composed of phospholipids and polymerized polydi-
acetylene lipids were shown to exhibit clearly visible color changes
upon interactions with antimicrobial membrane peptides. The
color changes in the system are due to a structural perturbation
of the lipids after their interactions with AMPs. The assay was also
valuable for detecting functionally related peptide analogs (Kolu-
sheva et al., 2000). Alamethicin, gramicidin, and valinomycin have
been investigated in such planar ﬁlm systems (Volinskya et al.,
2006). Otherwise, the in silico-based screening systems include
computerized methods as well as simulation methods that mimic
the interaction between peptides and membranes (Raventos et al.,
2005). A mathematical model has been developed to predict,
before synthesis, a peptide with an activity against P. aeruginosa
(Jenssen et al., 2008). Using original descriptors for assessing the
contact energy between spatially closed amino acids, as well as a
set of inductive and conventional quantitative structure–activity
relationship (QSAR) descriptors, it has been possible to model
the antibacterial activity of peptides before the synthesis step.
Cross-correlation and optimization of the selected descriptor val-
ues permitted these authors to build twomodels,using very limited
number of peptides. Even when such models were signiﬁcantly
different in size, no signiﬁcant difference was demonstrated in
their predictive power, meaning that it was possible to use this
tool to obtain useful and potent predictive models, even when
using small sets of peptides with different structures. The devel-
opment of biological assays in HTS has increased the number
of known antimicrobial structures allowing the development of
newer inductive QSAR descriptors, which in combination with
more complex mathematical algorithms, improve the in silico
identiﬁcation of novel HDPs (Hilpert et al., 2008). Also, QSAR
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descriptors have been developed for predicting antimicrobial pep-
tide toxicity against host cells (Langham et al., 2008). Additionally,
recent advances in molecular dynamics simulations of AMPs and
membrane mimics offer new data to help us to understand the
mechanism of action of these molecules (Langham and Kaznessis,
2010).
In a recent chemical approach, novel cationic AMPs were pro-
posed with a simple strategy using acid-amide substitution to
add a net positive charge to natural non-antibacterial amino acid
sequences showing structures thatwere different from the reported
cationicAMPs.Alterations produced inmembranes by thesemod-
iﬁed peptides were evaluated and conformational changes were
estimated from far-ultraviolet circular dichroism spectra. These
novel cationic AMPs showed sequences completely distant from
any other AMPs described before, suggesting that such modiﬁed
natural sequences could be an interesting source of novel frames
for cationic AMPs (Ueno et al., 2011).
LARGE-SCALE HDP PRODUCTION: OVERCOMING A MAIN
PROBLEM
Structural and functional features, as well as several other signif-
icant physiological characteristics of these molecules as described
in this review, are reasons why HDPs have received much attention
from the scientiﬁc community for the development of new phar-
maceuticals. However, there are real barriers in developing and
producing natural HDPs. The challenge begins with the under-
standing of the fundamental principles of action in HDPs, as
well as their structure–function relationship and pharmaceutical
potential (Wimley, 2010). The lack of this understanding has been
one of the major reasons why the development of these peptides
into new drugs has slowed. This is due to the fact that only a few
heterologous systems are capable of yielding a sufﬁcient amount
(in the range of∼50–690mg L−1) of soluble and puriﬁed peptides
in order to enlighten such extensive biological and structural ques-
tions (Xu et al., 2007; Li, 2009). Moreover, in order to accomplish
pharmaceutical and biotechnological goals, it is necessary to pro-
duce these peptides in large-scale. This sort of production has been
the biggest challenge in studies regarding screening, synthesis, and
characterization of these molecules.
Despite two decades of continuous efforts, the limitation of
small-scale production has impaired the successful use of HDPs in
health care. For instance, only four peptides to date have reached
global sales of over US$ 1 billion as therapeutic drugs. These
have been prescribed for treatments for multiple sclerosis as Glati-
ramer acetate (also known as Cop-1 or Copaxone; $3.8 billion),
for prostate cancer and breast cancer as leuprolide acetate (Lupron;
$2.12 billion) and goserelin acetate (Zoladex; $1.14 billion), and
for treatment of acromegaly and carcinoid syndrome as octreotide
acetate (Sandostatin; $1.12 billion; Peptide Therapeutics Founda-
tion, 2010 Report Summary). Moreover, in the last 5 years, only
one HDP, the human bactericidal/permeability-increasing protein
rBPI23 (Neuprex – indicated for treatment of meningococcal sep-
sis) has been approved for marketing. Furthermore, only three
HDPs have progressed to phase III of clinical-efﬁcacy trials (Pex-
iganan, Iseganan, and Omiganan) and none of these have to date
received FDA approval for clinical use (Hancock and Sahl, 2006;
Yeung et al., 2011).
To change this scenario, current approaches need to be reﬁned
and new technologies are required to be employed in the develop-
ment and production of HDPs. In order to recover and produce
peptides, different methods can be employed such as the direct
isolation fromnatural sources, chemical synthesis, or recombinant
expression. Theﬁrst strategy,despite extensive and efﬁcient utiliza-
tion at academic levels, it is extremely time-consuming and only
low amounts of peptides are recovered from the host organism.
This technique may even present environmental issues, especially
for peptides isolated from species that occur in low numbers in
nature (Li, 2011).
Chemical synthesis has been traditionally used to synthesize
short and simple molecules and has allowed for the production of
both natural and synthetic peptides (Zhou et al., 2010).However, it
is tremendously costly and practically unfeasible for the synthesis
of sequences larger than 15 residues of amino acids, running in the
range of US$ 100–600/g (Hancock and Sahl, 2006). Moreover, the
cost may increase substantially due to difﬁculties that arise dur-
ing synthesis of certain sequences such as those containing one
or more disulﬁde bonds, or showing multiple post-translational
modiﬁcations (Tay et al., 2011).
In view of the limits and inefﬁciencies of both methods
described above, the most widely used method is the heterolo-
gous expression system. In the last few decades, various systems
have been developed to reach a cost-effective and large-scale pro-
duction of several proteins (Huber et al., 2005) and HDPs such as
human defensins LL-37 and IDR-1 (Bommarius et al., 2010).
In most cases, the effectiveness of heterologous expression for
the production of HDPs involves the fusion of carrier proteins
containing an enzymatic or chemical cleavage site that allows
the target peptide to be released. Some of these proteins act as
stabilizing molecules due to their ability to neutralize the pos-
itive charge of the peptide, thus resulting in a non-toxic, efﬁ-
cient, and soluble expression of the target peptide (Rao et al.,
2004). According to the Recombinantly produced AMPs Database
(http://faculty.ist.unomaha.edu/; Li and Chen, 2008), the carrier
proteinmost frequently used is the thioredoxin, representingmore
than 20% of all reported fusion proteins, followed by the use of
GST (glutathione transferase –∼12%),PurF (amidophosphoribo-
syltransferase), and intein-mediated protein (∼8%). The SUMO
protein (small ubiquitin-related modiﬁer) has been a promising
carrier protein and has been shown to increase expression lev-
els as well as the solubility of peptides (Malakhov et al., 2004;
Bommarius et al., 2010).
The heterologous expression system may also be composed
of one or more epitope tags (Rubio et al., 2005). These are
short and hydrophilic peptide sequences recognized by speciﬁc
antibodies, thus offering efﬁcient detection. The most used epi-
tope tags are HA (YPYDVPDYA), FLAG (DYKDDDDK), cMyc
(EQKLISEEDL), and 6xHis (HHHHHH). Besides being used for
subcellular location, their small size provides efﬁcient afﬁnity
puriﬁcation and is more likely to interfere less with the peptide
of interest regarding its folding and function, when compared to
larger carrier proteins (Earley et al., 2006).
Among the available commercial options of heterologous
expression vectors, the most commonly used are those which
belong to the pET and pQE series, developed by Novagen and
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Qiagen, respectively. These vectors have been largely used for
expression of HDP derived from several organisms such as
defensins from humans (e.g., α-defensin 6), bovine (β-defensin
12) and defensin-like from fungus (plectasin; Wu et al., 2011b).
In addition, new mutant strains of E. coli BL21 (DE3) have been
developed to overcome the lethality caused by the expression of
AMPs (Li et al., 2010).
Regarding the prokaryotic systems, E. coli is the most popu-
lar organism used to express recombinant proteins. Due to its
features such as rapid growth rate, low cost, large availability for
commercial expression vectors, and extensive knowledge about its
genetics and physiology, E. coli has been applied to innumerable
studies of synthesis and expression of AMPs and HDPs from dif-
ferent organisms (Canales et al., 2011) and has also been used in
large-scale production of these peptides (Bommarius et al., 2010).
The limitation of the use of prokaryotic systems is to perform
post-translational modiﬁcations required for stability and bio-
logical activity of certain peptides. To overcome this limitation,
the use of eukaryotic systems is the appropriate approach. The
yeast species Pichia pastoris and Saccharomyces cerevisiae repre-
sent the most common eukaryotic host system used for expression
of heterologous proteins (Holz et al., 2002). The yeast P. pastoris
has been used for expression of HDPs derived from humans and
plants, although none have reported large-scale production (Yang
et al., 2007). Naturally, the disadvantage in using these organisms
is their innate sensitivity against antifungal peptides (Thevissen
et al., 2007).
Plants have been a promising alternative for eukaryotic systems
and numerous strategies have been developed to optimize these
organisms to attend commercial production (Desai et al., 2010).
The most common plant hosts are Nicotiana tabacum and Ara-
bidopsis thaliana, which have been reported in expression of AMPs
derived from plants such as LjAMP1, SmAMP1, and SmAMP2,
which have activities against 15 plant pathogens, including those
of economic concern. Furthermore, considering AMPs in plants
act like HDPs, such as defensins, the expression of these mole-
cules, either in plants or in bacteria, has been successfully achieved.
However, there is no report in the literature regarding expression
of HDPs from animal sources expressed in plants. Diverse studies
have demonstrated viable possibilities of using plants for produc-
tion of biotechnological products, contributing to the develop-
ment of new heterologous expression systems to reach large-scale
production (Pogue et al., 2010). Nevertheless, it should be empha-
sized that there needs to be advances in technology before these
organisms can be chosen over bacteria as an expression system for
recombinant HDPs.
The heterologous expression technologies overviewed here are
of paramount concern regarding the production of natural or
synthetic peptides in large-scale for therapeutic research and
development. The development of new technology and the wide-
spread acceptance of protein therapy as listed above will very
likely increase the percentage of HDPs and AMPs as therapeutic
candidates for pharmaceutical and biotechnological industries.
CONCLUDING REMARKS
As focused in this report, promiscuous AMPs and HDPs are evo-
lutionarily primordial defensive molecules widely distributed in
different kingdoms suggesting that they have played an essential
role in the development of multicellular organisms. This central
function comes from the fact that these promiscuous peptides
present the ability to bind to different targets. In addition to the
direct effects against microorganisms, HDPs also show the abil-
ity to act in the host organism, thus monopolizing the control
of infections at higher levels. This ability involves basic functions
of acquired immunity such as cytokine signal transduction, TLR
interaction, and primeval immune memory, thus acting as effec-
tive immunemodulators inmammals.Unfortunately, even though
research on HDPs has lead to a better understanding of their
functionality, the number of outbreaks is continuously increas-
ing while few alternatives are currently available to combat these
infections.
In order to control this increasing problem, novel strate-
gies for treating infectious illnesses will be necessary, requir-
ing additional manipulation of immune responses in order
to intensely diminish the infectious agents and also avoid
tissue wounds due to inﬂammation. The interchange ability
between immunogenicity, danger signaling, and immune mod-
ulation of HDPs could act in synergy with the immunity nor-
mally offered by humans. In this view, normal patients sub-
jected to resistant bacteria would clearly beneﬁt. Moreover,
patients with a compromised immune system subjected to severe
opportunistic infections could also have the opportunity to
improve their quality of life, reducing multiple infectious symp-
toms, e.g., fever, skin abscesses, chest pain, and shortness of
breath.
Nevertheless, many problems must be solved for efﬁcient HDP
selection and production. Regarding the selection issue, novel
compounds must be screened from different and unusual sources
exploring different biomes and environments. The production
problems must be solved by using novel technologies of chemical
synthesis, and also novel strategies of heterologous production.
An additional problem is the low stability of some peptides. This
can be improved by several methods including the production
of mutants and also the design of novel particles that could
protect the peptide against host–hostile environments, provid-
ing an efﬁcient delivery system. One must ask whether peptides
are capable of correctly modulating the host immune system. If
not, the collateral effects will be worse than the proper infection.
This does not seem to be the case, at least when considering the
many trials using animal models. Nevertheless, several clinical
trials using human beings must be performed in order to pro-
vide security for all patients. The use of the AMPs or HDPs is
inevitable and extremely desirable, but more studies must be per-
formed in order to really understand the mechanisms of action
of such molecules. Indeed, researchers must use all the available
technology possible including proteomics, genomics, transcrip-
tomics, nanobiotechnology, and many others in order to reduce
the detrimental effects on the population. The infectious storm is
upon the human species and the best that we can do is be pre-
pared for it by constructing and producing the best compounds
possible.
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